Medicine & Life Sciences

1. Cystic Fibrosis 100%
2. Chronic Obstructive Pulmonary Disease 80%
3. GS-5734 67%
4. Lung 45%
5. Emphysema 33%
6. Placebos 31%
7. Spirometry 28%
8. Coronavirus 25%
9. baricitinib 24%
10. ivacaftor 24%
11. Cystic Fibrosis Transmembrane Conductance Regulator 22%
12. SARS Virus 21%
13. Smokers 20%
14. Obstructive Lung Diseases 18%
15. Biomarkers 16%
16. Molecular Epidemiology 14%
17. Smoking 14%
18. Insulin Secretion 13%
19. ivacaftor drug combination lumacaftor 12%
20. Forced Expiratory Volume 12%
21. Disease Progression 12%
22. Mortality 12%
23. Chest Wall Oscillation 12%
24. Pseudomonas Infections 12%
25. Respiratory Tract Infections 11%
26. Viruses 11%
27. dornase alfa 11%
28. Incidence 11%
29. Phenotype 11%
30. Adenomatous Polyps 11%
31. Safety 10%
32. Transplant Recipients 10%
33. Randomized Controlled Trials 10%
34. Interferon beta-1a 10%
35. Tiotropium Bromide 10%
36. Chronic Bronchitis 10%
37. Ipratropium 9%
38. Confidence Intervals 9%
39. Sputum 9%
40. Retrospective Studies 9%
41. Equivalence Trials 9%
42. Vaccination 8%
43. Single Nucleotide Polymorphism 8%
44. Tobramycin 8%
45. Lung Transplantation 8%
46. Angiotensin Receptors 8%
47. Azithromycin 8%
48. Bronchiolitis Obliterans 8%
49. Premedication 8%